Pharmaceuticals, Biotechnology and Life Sciences
David Meek, Chief Executive Officer of Ipsen, said that the company’s performance in the first half of 2017 exceeded expectations, leading to an improved financial outlook for the full year.
Bavarian Nordic has announced an additional worldwide exclusive license and collaboration agreement with Janssen Pharmaceuticals, which grants Janssen the exclusive rights to Bavarian Nordic’s MVA-BN technology for two programs, targeting vaccines against hepatitis B virus (HBV) and the human immunodeficiency virus (HIV-1).
AstraZeneca and Merck on Thursday said that they have made a deal to co-develop and co-commercialise AstraZeneca’s oncology product Lynparza (olaparib) for multiple cancer types. Lynparza is an oral poly ADP ribose polymerase (PARP) inhibitor currently approved for BRCA-mutated ovarian cancer in multiple lines of treatment.
Arix Bioscience has co-led an oversubscribed Series A financing round raising $29 million for PreciThera, a new Arix Group Business focused on developing novel biological therapeutics to treat orphan bone diseases.
AstraZeneca today announced that the European Commission (EC) has approved Faslodex (fulvestrant) for certain metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy.
Quantum Genomics, a biopharmaceutical company focused on cardiovascular diseases, has a completed placement and a capital increase, including the removal of preferential subscription rights, reserved for a category of beneficiaries.
Ablynx was granted Fast Track designation for caplacizumab, by the that the U.S. Food and Drug Administration (FDA). That’s the company’s first-in-class anti-von Willebrand factor (vWF) Nanobody developed for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP).
Verona Pharma, a respiratory disease-focused drugmaker, said on Wednesday that the first patients have been dosed in a Phase 2b clinical trial testing RPL554 as a maintenance treatment for chronic obstructive pulmonary disease (COPD). Verona Pharma expects to report top-line data from this trial in the second half of 2018.
Midatech Pharma has prepared its candidate MTD119 (previously MTR104) for advanced liver cancer for the clinical testings, in a pre-clinical programme that included three subcutaneous or orthotopic liver cancer xenograft models treated with the active cytotoxic compound maytansine conjugated with Midatech’s gold nanoparticle (GNP) technology.
HedgePath Pharmaceuticals said on Tuesday that the U.S. Food and Drug Administration (FDA) has provided further guidance regarding HPPI’s ongoing, open-label Phase 2 clinical trial studying the effect of SUBA-Itraconazole (SUBA-Cap) oral capsules in patients with Basal Cell Carcinoma Nevus Syndrome (BCCNS), also known as Gorlin Syndrome.